(Press-News.org) PORTLAND, OR - Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients three and one-half years after the last patient enrolled to the trial. They did find, however, that patients taking pembrolizumab had fewer serious side effects than those treated with either high-dose interferon or ipilimumab.
The S1404 trial is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), designed and led by the SWOG Cancer Research Network, and conducted by the NIH-funded National Clinical Trials Network (NCTN).
Kenneth F. Grossmann, MD, PhD, of the Huntsman Cancer Institute at the University of Utah Medical Center and chair of SWOG's Melanoma Committee was lead investigator on the study. He spoke about the pembrolizumab treatment that was tested: "The recurrence-free survival advantage and improved safety profile over the previous standard of care make this therapy a continued standard for treating patients with high-risk resected melanoma."
Noting that overall survival measures were not significantly different between the two arms, Grossmann said, "The overall survival analysis was performed at a pre-defined time point with only approximately 50% of events needed for a fully powered analysis. We suspect that effective use of PD-1 blockade and other improved therapies for stage IV disease improved outcomes of relapsing patients on the control arm such that overall survival was not different between the two groups."
Grossmann added that further data to come from this trial will include studies to evaluate pre-treatment predictors of whether patients are likely to benefit from treatment and quality of life studies to better understand the impact of relapse in patients with high-risk resectable melanoma.
The study randomized 1,345 adult patients with stage III or IV melanoma who had undergone surgery to remove their tumors. Patients were assigned at random to either the pembrolizumab arm or the control arm. Those on the control arm decided with their physicians whether to follow a course of high-dose interferon or a course of ipilimumab, both of which are approved by the FDA for use in treating these patients.
Pembrolizumab, an immunotherapy drug known as a PD-1 inhibitor, was chosen for the trial because of its comparatively low toxicity and its activity in metastatic disease. Another trial has also since shown a recurrence-free survival benefit for the drug when compared to a placebo. High-dose interferon and ipilimumab, which were standard of care treatments for these patients at the start of the study, often come with serious side effects. As the S1404 researchers had expected, toxicity was lower in patients on the pembrolizumab arm. Among patients taking high-dose interferon, roughly 72% had severe side effects (grade 3 or higher adverse events). The rate of such side effects was about 58% for those on ipilimumab, but it was only about 32% for patients on pembrolizumab.
INFORMATION:
S1404 was funded by the NIH through grants CA180888, CA180819, CA180820, and CA180863 and in part by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., through a Cooperative Research and Development Agreement between NCI and Merck.
The S1404 study team included Megan Othus, PhD, of the SWOG Statistics and Data Management Center; Sapna Patel, MD, of the MD Anderson Cancer Center; Ahmad Tarhini, MD, PhD, and Vernon K. Sondak, MD, of the Moffitt Cancer Center; Teresa M. Petrella, MD, MHSc, of the Odette Cancer Center; Thach-Giao Truong, MD, of Kaiser Permanente NCAL; Nikhil Khushalani, MD, of the Moffitt Cancer Center; Justine V. Cohen, DO, of Massachusetts General Hospital; Elizabeth I. Buchbinder, MD, of the Dana Farber Cancer Institute; Kari Kendra, MD, PhD, of The Ohio State University; Pauline Funchain, MD, of the Cleveland Clinic; Karl D. Lewis, MD, of the University of Colorado Cancer Center; Bartosz Chmielowski, MD, PhD, of the Jonsson Comprehensive Cancer Center; Hongli Li, MS, and James Moon, MS, of the SWOG Statistics and Data Management Center; Krishna S. Gunturu, MD, of Lahey Hospital and Medical Center; Zeynep Eroglu, MD, of the Moffitt Cancer Center; John M. Kirkwood, MD, of the University of Pittsburgh Medical Center; and Antoni Ribas, MD, PhD, of the Jonsson Comprehensive Cancer Center.
SWOG Cancer Research Network is part of the National Cancer Institute's National Clinical Trials Network and the NCI Community Oncology Research Program and is part of the oldest and largest publicly funded cancer research network in the nation. SWOG has nearly 12,000 members in 47 states and seven foreign countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at swog.org.
One of the world's most endangered whale species could have added protection from threats posed by human marine activity, through technology developed by the University of East Anglia (UEA).
In partnership with the Scottish Association for Marine Science (SAMS) and the marine survey company Gardline Geosurvey Limited, UEA researchers have developed machine learning techniques that can be used to detect the presence of North Atlantic right whales by listening for the sounds they make underwater.
Detecting the animals' presence before they reach close proximity ...
When saber-toothed tigers, woolly mammoths and giant sloths roamed North America during the last Ice Age about 18,000 to 80,000 years ago, the Gulf Coast's climate was only slightly cooler, more similar to regions to the north like Missouri and North Carolina's climate today. As sea level dropped and exposed more land on the continental shelf, bald cypress trees became established in swamps in what is now the northern Gulf of Mexico.
An event occurred and suddenly killed and buried the bald cypress forests along the Gulf Coast. The buried swamp trees were preserved by sediment for thousands of years. About 18,000 years ago, sea level rose. As the ocean waters moved inland, the buried trees were preserved in their ...
HOUSTON - (June 3, 2021) - Postpartum women in bad romantic relationships are not only more likely to suffer symptoms of depression, they are also at greater long-term risk of illness or death, according to new research from Rice University, Ohio State University and the University of California, Irvine.
"Longitudinal changes in HRV across pregnancy and postpartum: Effect of negative partner relationship qualities" will appear in the July 2021 edition of Psychoneuroendocrinology. The researchers examined how relationships and partner behavior are linked to depression and heart rate variability (HRV) in women between the third trimester of pregnancy and one year postpartum.
"The quality ...
While early detection of breast cancer is critical, early prediction of how well the neoadjuvant chemotherapy treatment before surgery is working also may provide a window of opportunity when treatment could be altered and have a big impact on the patient's quality of life.
An interdisciplinary team of researchers at Washington University in St. Louis has found that combining data from tumor biomarkers, ultrasound, and ultrasound-guided diffuse optical tomography (DOT) after a patient's first cycle of pre-surgical neoadjuvant chemotherapy provided a highly accurate prediction of how the tumor was responding to the treatment. The results from a clinical trial at Washington University School of Medicine and Barnes-Jewish ...
RESEARCHERS at the University of Huddersfield have warned there is an urgent need for the country's mental health interventions to create strategies optimising the use of antidepressants after conducting a study which has highlighted an alarming rise in relation to usage and costs.
The open-access study, published by the international DARU Journal of Pharmaceutical Sciences, is entitled 'Surging trends in prescriptions and costs of antidepressants in England amid COVID-19' and has investigated the trends in prescriptions and costs of various antidepressants in England during the COVID-19 pandemic.
The researchers discovered that the total number of antidepressant prescriptions drugs dispensed during ...
When bringing technologies into the workplace, it pays to be realistic. Often, for instance, bringing new digital technology into an organization does not radically improve a firm's operations. Despite high-level planning, a more frequent result is the messy process of frontline employees figuring out how they can get tech tools to help them to some degree.
That task can easily fall on overburdened workers who have to grapple with getting things done, but don't always have much voice in an organization. So isn't there a way to think systematically about implementing digital technology in the workplace?
MIT Professor Kate Kellogg thinks there is, and calls it "experimentalist governance of digital technology": Let different parts of an organization experiment with the technology -- ...
A new study by ecologist André de Roos* shows that differences between juveniles and adults of the same species are crucial for the stability of complex ecological communities. The research, published in Proceedings of the National Academy of Sciences, represents a major advance in ecological modeling at a time when biodiversity is declining and species around the world are rapidly going extinct.
Up to now, ecological models have focused exclusively on the interactions between species, ignoring the variations within them. The dragonflies, frogs, trout, and phytoplankton in a freshwater pond, for example, would be represented as nodes in a network, connected by edges that ...
LAWRENCE -- A strange thing sometimes happens when we listen to a spoken phrase again and again: It begins to sound like a song.
This phenomenon, called the "speech-to-song illusion," can offer a window into how the mind operates and give insight into conditions that affect people's ability to communicate, like aphasia and aging people's decreased ability to recall words.
Now, researchers from the University of Kansas have published a study in PLOS ONE examining if the speech-to-song illusion happens in adults who are 55 or older as powerfully as it does with younger ...
(SACRAMENTO, Calif.) - An international team of researchers, led by END ...
Alexandria, Va., USA -- Dental care professionals are thought to be at enhanced risk of occupational exposure to SARS-CoV-2, but robust data to support this is lacking. The study "COVID-19: Seroprevalence and Vaccine Responses in UK Dental Care Professionals," published in the Journal of Dental Research (JDR), provides a longitudinal analysis of antibodies to SARS-CoV-2 spike glycoprotein, including early analysis of the impact of vaccination on the immune response.
In June 2020, I,507 West Midlands dental care professionals were recruited to test for baseline seroprevalence, or the proportion of the population that have circulating antibodies to SARS-CoV-2, indicating prior ...
